Pages that link to "Q33156176"
Jump to navigation
Jump to search
The following pages link to Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects (Q33156176):
Displaying 50 items.
- Efficacy of alogliptin in type 2 diabetes treatment: a meta-analysis of randomized double-blind controlled studies (Q24288949) (← links)
- Regulation of glucose homeostasis by GLP-1 (Q24563430) (← links)
- Nitrile-containing pharmaceuticals: efficacious roles of the nitrile pharmacophore (Q24569706) (← links)
- Role of dipeptidyl peptidase-4 inhibitors in new-onset diabetes after transplantation (Q26778329) (← links)
- Alogliptin benzoate for management of type 2 diabetes (Q28083933) (← links)
- Alogliptin in combination with metformin and pioglitazone for the treatment of type 2 diabetes mellitus (Q33874654) (← links)
- Diabetes treatment in patients with renal disease: Is the landscape clear enough? (Q34068430) (← links)
- Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment (Q34139048) (← links)
- Alogliptin: a new addition to the class of DPP-4 inhibitors (Q34620671) (← links)
- Clinical pharmacokinetics and pharmacodynamics of linagliptin. (Q34638128) (← links)
- Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy (Q35026483) (← links)
- Application of pharmacometric approaches to evaluate effect of weight and renal function on pharmacokinetics of alogliptin (Q36706802) (← links)
- Dietary resistant starch upregulates total GLP-1 and PYY in a sustained day-long manner through fermentation in rodents (Q36976985) (← links)
- Dipeptidyl Peptidase-4 Inhibitor Increases Vascular Leakage in Retina through VE-cadherin Phosphorylation (Q37067760) (← links)
- Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus (Q37735838) (← links)
- Incretin-based therapies: review of the outpatient literature with implications for use in the hospital and after discharge (Q37780914) (← links)
- Alogliptin: a review of its use in the management of type 2 diabetes mellitus (Q37794971) (← links)
- Small molecule dipeptidylpeptidase IV inhibitors under investigation for diabetes mellitus therapy (Q37866299) (← links)
- Linagliptin: a novel dipeptidyl peptidase 4 inhibitor with a unique place in therapy (Q37878396) (← links)
- Clinical Pharmacology of Incretin Therapies for Type 2 Diabetes Mellitus: Implications for Treatment (Q37888162) (← links)
- Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences. (Q37910902) (← links)
- Incretin therapies in the management of patients with type 2 diabetes mellitus and renal impairment (Q38012068) (← links)
- Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors (Q38017726) (← links)
- Renal and cardiac effects of DPP4 inhibitors--from preclinical development to clinical research (Q38040596) (← links)
- New strategy for the treatment of type 2 diabetes mellitus with incretin-based therapy (Q38058463) (← links)
- Alogliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes mellitus (Q38167010) (← links)
- Alogliptin: A new dipeptidyl peptidase-4 inhibitor for the management of type 2 diabetes mellitus (Q38174536) (← links)
- Alogliptin (Q38178240) (← links)
- Pharmacokinetics, safety, and efficacy of DPP-4 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus and renal or hepatic impairment. A systematic review of the literature (Q38186638) (← links)
- Alogliptin benzoate for the treatment of type 2 diabetes (Q38197275) (← links)
- Dipeptidyl peptidase-4 inhibitors: pharmacokinetics, efficacy, tolerability and safety in renal impairment. (Q38200670) (← links)
- The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected]. (Q38205588) (← links)
- Linagliptin: from bench to bedside (Q38213703) (← links)
- DPP-4 inhibitors: pharmacological differences and their clinical implications (Q38244576) (← links)
- Alogliptin: a review of its use in patients with type 2 diabetes mellitus (Q38412153) (← links)
- Pharmacokinetics and clinical evaluation of the alogliptin plus pioglitazone combination for type 2 diabetes (Q38455771) (← links)
- Diabetes therapies in hemodialysis patients: Dipeptidase-4 inhibitors (Q38541323) (← links)
- Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus (Q38546981) (← links)
- An update on the clinical pharmacology of the dipeptidyl peptidase 4 inhibitor alogliptin used for the treatment of type 2 diabetes mellitus (Q38556037) (← links)
- Alogliptin for the treatment of type 2 diabetes: a drug safety evaluation (Q38647717) (← links)
- Acute DPP-4 inhibition modulates vascular tone through GLP-1 independent pathways (Q40652421) (← links)
- Characterization of the post-prandial insulinemic response and low glycaemic index of a soy beverage (Q41326923) (← links)
- Clinical pharmacology of alogliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of Type 2 diabetes (Q42723596) (← links)
- DPP-4 (CD26) inhibitor alogliptin inhibits TLR4-mediated ERK activation and ERK-dependent MMP-1 expression by U937 histiocytes (Q42906627) (← links)
- Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis (Q42987834) (← links)
- The dipeptidyl peptidase-4 inhibitor alogliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis (Q45877987) (← links)
- Coadministration of pioglitazone or glyburide and alogliptin: pharmacokinetic drug interaction assessment in healthy participants. (Q45923722) (← links)
- Quantitative Model of the Relationship Between Dipeptidyl Peptidase‐4 (DPP‐4) Inhibition and Response: Meta‐Analysis of Alogliptin, Saxagliptin, Sitagliptin, and Vildagliptin Efficacy Results (Q46866125) (← links)
- Evaluation of drug efficacy of DPP-4 inhibitors based on theoretical analysis with pharmacokinetics and pharmacodynamics (Q48152264) (← links)
- Immunohistochemistry for Anti-diabetes Drug, Alogliptin Using a Newly Prepared Monoclonal Antibody: Its Precise Localization in Rat Small Intestine (Q64107952) (← links)